Mylan (NSDQ:MYL) and Theravance Biopharma, Inc. (NSDQ:TBPH) said today that revefenacin, the 1st nebulized bronchodilator in development for the treatment of chronic obstructive pulmonary disease(COPD), demonstrated positive results in 2 replicate phase III efficacy studies.
Data from more than 1,250 moderate to severe COPD patients show that both studies met their efficacy and safety endpoints. Revefenacin demonstrated statistically significant improvements to COPD symptoms over the course of 12 weeks compared to a placebo.
Get the full story at our sister site, Drug Delivery Business News.
The post Mylan, Theravance touts Phase III data for COPD drug appeared first on MassDevice.
from MassDevice http://ift.tt/2dDqTrD
Cap comentari:
Publica un comentari a l'entrada